Matrix metalloproteinase-9 gene polymorphism (-1562 C/T) and its correlation with diabetic nephropathy

Ritz E, Rychlík I, Locatelli F, Halimi S (1999) End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 34(5):795–808 Tuttle KR, Bakris GL, Bilous RW, Chiang JL, De Boer IH, Goldstein-Fuchs J, Neumiller JJ (2014) Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis 64(4):510–533 Gheith O, Othman N, Maher A, Rida S, Halim MA, Abduo H, Al-Otaibi T (2018) Prevalence of diabetic kidney disease before and after renal transplantation in Arab countries. J Egypt Soc Nephrol Transplant 18(3):59 Wolf G (2004) New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 34(12):785–796 Martini S, Eichinger F, Nair V, Kretzler M (2008) Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge. Rev Endocr Metab Disord 9(4):267–274 Cooper ME (2001) Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44(11):1957–1972 Zaoui P, Cantin JF, Alimardani-Bessette M, Monier F, Halimi S, Morei F, Cordonnier D (2000) Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions. Diabete Metab 26:25–29 van der Zijl NJ, Hanemaaijer R, Tushuizen ME, Schindhelm RK, Boerop J, Rustemeijer C, Diamant M (2010) Urinary matrix metalloproteinase-8 and-9 activities in type 2 diabetic subjects: a marker of incipient diabetic nephropathy? Clin Biochem 43(7-8):635–639 Ebihara I, Nakamura T, Shimada N, Koide H (1998) Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 32(4):544–550 Clark IM, Swingler TE, Sampieri CL, Edwards DR (2008) The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40(6-7):1362–1378 Zhang Z, Wu X, Cai T, Gao W, Zhou X, Zhao J, Liao L (2015) Matrix metalloproteinase 9 gene promoter (rs 3918242) mutation reduces the risk of diabetic microvascular complications. Int J Environ Res Public Health 12(7):8023–8033 Kruger DF, Boucher JL, Banerji MA (2011) Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus. Postgrad Med 123(4):54–62 Feng S, Ye G, Bai S, Wei H, Liao X, Li L (2016) Matrix metalloproteinase-9− 1562C/T gene polymorphism is associated with diabetic nephropathy. Biomed Res Int 2016, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007315/ Satirapoj B, Adler SG (2014) Comprehensive approach to diabetic nephropathy. Kidney Res Clin Pract 33(3):121–131 Umanath K, Lewis JB (2018) Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis 71(6):884–895 Ho HY, Lin CW, Chien MH, Reiter RJ, Su SC, Hsieh YH, Yang SF (2016) Melatonin suppresses TPA-induced metastasis by downregulating matrix metalloproteinase-9 expression through JNK/SP-1 signaling in nasopharyngeal carcinoma. J Pineal Res 61(4):479–492 Bai Y, Wang L, Li Y, Liu S, Li J, Wang H, Huang H (2006) High ambient glucose levels modulates the production of MMP-9 and a5 (IV) collagen by cultured podocytes. Cell Physiol Biochem 17(1-2):57–68 Beránek M, Kolar P, Tschoplova S, Kankova K, Vasku A (2008) Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Mol Vis 14:1114 Ahluwalia TS, Khullar M, Ahuja M, Kohli HS, Bhansali A, Mohan V, Venkatesan R, Rai TS, Sud K, Singal PK (2009) Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 4(4):e5168 Singh K, Agrawal NK, Gupta SK, Singh K (2013) A functional single nucleotide polymorphism-1562C > T in the matrix metalloproteinase-9 promoter is associated with type 2 diabetes and diabetic foot ulcers. Int J Low Extrem Wounds 12(3):199–204 Palazhy S, Viswanathan V (2017) Lipid abnormalities in type 2 diabetes mellitus patients with overt nephropathy. Diabetes Metab J 41(2):128–134 De Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J (2011) Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305:2532–2539 Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG (2006) Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 296:421–426 Neugarten J, Golestaneh L (2013) Gender and the prevalence and progression of renal disease. Adv Chronic Kidney Dis 20(5):390–395 Gheith O, Othman N, Nampoory N, Halimb MA, Al-Otaibi T (2016) Diabetic kidney disease: difference in the prevalence and risk factors worldwide. J Egypt Soc Nephrol Transplant 16(3):65 Russo GT, De Cosmo S, Viazzi F, Mirijello A, Ceriello A, Guida P, Giorda C, Cucinotta D, Pontremoli R, Fioretto P (2018) AMD-Annals Study Group. Diabetic kidney disease in the elderly: prevalence and clinical correlates. BMC Geriatr 18(1):38 Huang ES (2016) Management of diabetes mellitus in older people with comorbidities. BMJ 353:i2200 Van Buren PN, Toto R (2011) Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis 18(1):28–41 Low SK, Sum CF, Yeoh LY, Tavintharan S, Ng XW, Lee SB, Lim SC (2015) Prevalence of chronic kidney disease in adults with type 2 diabetes mellitus. Ann Acad Med Singapore 44(5):164–171 Okada H, Fukui M, Tanaka M, Matsumoto S, Mineoka Y, Nakanishi N, Nakamura N (2013) Visit-to-visit blood pressure variability is a novel risk factor for the development and progression of diabetic nephropathy in patients with type 2 diabetes. Diabetes Care 36(7):1908–1912 Lin CC, Chen CC, Chen FN, Li CI, Liu CS, Lin WY, Li TC (2013) Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose. Am J Med 126(11):1017–10e1